Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30771
Title: The relationship between Nephrocheck® test values, outcomes, and urinary output in critically ill patients at risk of acute kidney injury.
Austin Authors: Naorungroj, Thummaporn ;Yanase, Fumitaka ;Bittar, Intissar ;Eastwood, Glenn M ;Bellomo, Rinaldo 
Affiliation: Department of Intensive Care, Royal Melbourne Hospital, Melbourne, Victoria, Australia
Pathology
Department of Critical Care, University of Melbourne, Melbourne, Victoria, Australia
Data Analytics Research and Evaluation (DARE) Centre
Intensive Care
Department of Intensive Care, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand..
ANZICS-Research Centre, Melbourne, Victoria, Australia
Monash University School and Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
Issue Date: 19-Aug-2022
Date: 2022
Publication information: Acta Anaesthesiologica Scandinavica 2022-11; 66(10): 1219-1227
Abstract: Nephrocheck® was approved for acute kidney injury (AKI) risk assessment in critically illness. However, new studies suggest that urinary concentration affects Nephrocheck® and previous studies did not provide data on urinary output (UO) at the time of measurement. We performed a prospective cohort study of the Nephrocheck® in intensive care unit patients fulfilling standard inclusion criteria. The primary outcome was Stage 2 or 3 AKI defined by both UO and creatinine Kidney Disease Improving Global Outcomes (KDIGO) criteria in the subsequent 12 h. The secondary outcome was the relationship of UO with Nephrocheck® measurement. Among 98 patients, the primary outcome occurred in 53 (54.1%) overall, but in 23 (23.5%) by creatinine criteria alone. The median (interquartile range) Nephrocheck® in patients with subsequent Stage 2 or 3 AKI was greater than in Stage 1 or no-AKI patients (0.97 [0.48-1.99] vs. 0.46 [0.22-1.17]; p = .005). However, its area under the receiver characteristic curve was 0.66 (95% confidence interval [CI], 0.56-0.77). Moreover, Nephrocheck® was significantly and inversely correlated with UO (ρ = -.46, p < .001) at the time of measurement and, on a multivariable logistic regression, Nephrocheck® was not associated with subsequent Stage 2 or 3 AKI (OR 1.06 [95% CI, 0.74-1.53], p = .73). In contrast, the UO had an OR of 0.98 for each ml/h increase (95% CI, 0.97-1.00, p = .007). Nephrocheck®'s predictive performance was limited and its value was inversely correlated with UO. Nephrocheck® had no independent relationship with outcome once UO at measurement was considered.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30771
DOI: 10.1111/aas.14133
ORCID: https://orcid.org/0000-0001-6562-4891
Journal: Acta Anaesthesiologica Scandinavica
PubMed URL: 36056749
Type: Journal Article
Subjects: acute kidney injury
creatinine
insulin-liked growth factor binding protein 7
tissue inhibitor of metalloproteinase-2
urine output
Appears in Collections:Journal articles

Show full item record

Page view(s)

72
checked on Dec 26, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.